| |
|
|
Clinical Proof
|
| Genistein, is the most widely studied and well documented of all isoflavones and has been classified as GRAS (Generally Regarded As Safe) by US Federal Drug Administration. |
| SAFETY |
| Study |
: |
J. Clin. Endocrin. Metab. Sept 16,2008, doi:10.1210/jc.2008-1087. |
| Objective |
: |
Assessment on Safety Profile of Genistein on Breast and endometrium and it’s effect on bone after 3 years of therapy. |
| Conclusion |
: |
After 3 years of treatment, Genistein exhibited a promising safety profile with no significant change in mammographic breast density or endometrial thickness and exhibits positive effects on bone formation in postmenopausal women. After 3 years of treatment, Genistein exhibited a promising safety profile with no significant change in mammographic breast density or endometrial thickness and exhibits positive effects on bone formation in postmenopausal women.
|
|
|
|
|
|
